Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects

Abstract

Background

Here, we aimed to investigate the pharmacokinetics of abacavir and carbovir triphosphate (CBV-TP) with darunavir/ritonavir 900/100 mg once daily or raltegravir 400 mg twice daily.

Methods

HIV-infected subjects on abacavir (600 mg once daily) underwent steady-state pharmacokinetic assessments without and with darunavir/ritonavir or raltegravir. Within-subject changes in plasma and intracellular pharmacokinetic parameters were evaluated by geometric mean ratios (GMRs) and 90% CIs.

Results

A total of 19 patients completed the study. With darunavir/ritonavir (versus abacavir alone), abacavir GMRs (90% CI) were 0.73 (0.66, 0.80), 0.62 (0.50, 0.77) and 0.78 (0.69, 0.87) for area under the curve (AUC), trough concentration (C_trough) and maximum concentration (C_max), respectively. With raltegravir, they were 1.03 (0.97, 1.10), 0.83 (0.62, 1.11) and 1.06 (0.95, 1.18), respectively. Intracellular CBV-TP GMRs (90% CI) were 0.88 (0.72, 1.07), 0.68 (0.48, 0.95) and 0.98 (0.79, 1.23) for AUC, C_trough and C_max, respectively, with darunavir/ritonavir, and 0.96 (0.76, 1.20), 0.57 (0.33, 1.00) and 1.07 (0.85, 1.35), respectively, with raltegravir.

Conclusions

There was a 27% decrease in abacavir plasma exposure with darunavir/ritonavir and no changes with raltegravir. CBV-TP C_trough was significantly decreased with darunavir/ritonavir (32%) and showed a high inter-individual variability with raltegravir.

References

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents 2009. Department of Health and Human Services. (Updated 10 January 2011. Accessed 5 September 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Boffito

, Acosta

, Burger

Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther 2005; 10: 469–477.

Piliero

P.J.

Pharmacokinetic properties of nucleoside/ nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004; 37 Suppl 1: S2–S12.

Kewn

, Hoggard

P.G.

, Sales

S.D.

Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2002; 46: 135–143.

Anderson

P.L.

, Kakuda

T.N.

, Kawle

, Fletcher

C.V.

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17: 2159–2168.

Foster

R.H.

, Faulds

Abacavir. Drugs 1998; 55: 729–736.

Moyle

G.J.

, DeJesus

, Cahn

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38: 417–425.

Smith

K.Y.

, Patel

, Fine

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23: 1547–1556.

Moyle

, Boffito

, Fletcher

Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2009; 53: 1532–1538.

10.

Sax

P.E.

, Tierney

, Collier

A.C.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361: 2230–2240.

11.

Aptivus (tipranavir). Package insert 2011. Boehringer– Ingelheim

Ridgefield, CT, USA.

12.

Waters

, Fisher

, Winston

A Phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 2011; 25: 65–71.

13.

McKeage

, Perry

C.M.

, Keam

S.J.

Darunavir: a review of its use in the management of HIV infection in adults. Drugs 2009; 69: 477–503.

14.

Burger

D.M.

Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin Drug Metab Toxicol 2010; 6: 1151–1160.

15.

Else

, Watson

, Tjia

Validation of a rapid and sensitive high-performance liquid chromatographytandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455–1465.

16.

Curran

, Gutirerrez

, Deig

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients. J Antimicrob Chemother 2010; 65: 2195–2203.

17.

Hoggard

P.G.

, Sales

S.D.

, Kewn

Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro. Antivir Chem Chemother 2000; 11: 353–358.

18.

Markowitz

, Morales-Ramirez

J.O.

, Nguyen

B.Y.

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43: 509–515.

19.

Waters

L.J.

, Moyle

, Bonora

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther 2007; 12: 825–830.

20.

Gao

W.Y.

, Shirasaka

, Johns

D.G.

, Broder

, Mitsuya

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993; 91: 2326–2333.

21.

Ray

A.S.

Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev 2005; 7: 113–125.

22.

Goicoechea

, Jain

, Bi

Interlaboratory measurement differences in intracellular carbovir triphosphate concentrations in HIV-infected patients: sources of variability in processing, shipping, and quantitation. J Clin Pharmacol 2010; 50: 968–974.

23.

Young

, Vanig

, Dejesus

A pilot study of abacavir/ lamivudine and raltegravir in antiretroviral-naive HIV-1-infected patients: 48-week results of the SHIELD Trial. HIV Clin Trials 2010; 11: 260–269.